Hans Ehrencrona

List of Publications by Year in Descending Order

86 papers	5,674 citations	37 h-index	75 g-index
90 ext. papers	6,735 ext. citations	8.6 avg, IF	3.99 L-index

#	Paper	IF	Citations
86	FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study. *Blood*, **2021**, 138, 633-633	2.2	0
85	A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients. *Scientific Reports*, **2021**, 11, 14763	4.9	0
84	Genetic testing in women with early-onset breast cancer: a Traceback pilot study. *Breast Cancer Research and Treatment*, **2021**, 190, 307-315	4.4	
83	Variations in the Referral Pattern for Genetic Counseling of Patients with Early-Onset Breast Cancer: A Population-Based Study in Southern Sweden. *Public Health Genomics*, **2020**, 23, 100-109	1.9	1
82	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. *Journal of the National Cancer Institute*, **2020**, 112, 1242-1250	9.7	51
81	The Spectrum of Protein Truncating Variants in European Breast Cancer Cases. *Cancers*, **2020**, 12,	6.6	7
80	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
79	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. *Journal of Clinical Oncology*, **2020**, 38, 674-685	2.2	133
78	Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. *Nature Communications*, **2020**, 11, 3747	17.4	18
77	Public support for healthcare-mediated disclosure of hereditary cancer risk information: Results from a population-based survey in Sweden. *Hereditary Cancer in Clinical Practice*, **2020**, 18, 18	2.3	0
76	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. *Human Mutation*, **2019**, 40, 1557-1578	4.7	52
75	Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. *Nature Medicine*, **2019**, 25, 1526-1533	50.5	102
74	Hereditary colorectal cancer diagnostics in southern Sweden: retrospective evaluation and future considerations with emphasis on Lynch syndrome. *Journal of Community Genetics*, **2019**, 10, 259-266	2.5	1
73	CliniciansRuse of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey. *Journal of Community Genetics*, **2019**, 10, 61-71	2.5	5
72	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
71	Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. *Lancet Oncology, The*, **2018**, 19, 747-757	21.7	281
70	The c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. *Journal of Medical Genetics*, **2018**, 55, 15-20	5.8	36

69	Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries. *Familial Cancer*, **2018**, 17, 31-41	3	6
68	Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. *Genetics in Medicine*, **2018**, 20, 452-457	8.1	44
67	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
66	Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. *Leukemia*, **2017**, 31, 1108-1116	10.7	134
65	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	153
64	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
63	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
62	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
61	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
60	Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial. *Blood*, **2016**, 128, 787-787	2.2	32
59	No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial. *Blood*, **2016**, 128, 789-789	2.2	9
58	FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. *Human Molecular Genetics*, **2015**, 24, 5345-55	5.6	68
57	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
56	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
55	Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). *European Journal of Haematology*, **2015**, 94, 243-50	3.8	47
54	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
53	Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. *Leukemia*, **2015**, 29, 999-1003	10.7	229
52	Mature, Adaptive-like CD56DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission. *Blood*, **2015**, 126, 343-343	2.2	3

51	RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib. *Leukemia*, **2014**, 28, 977-9	10.7	39
50	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
49	Functional implications of the p.Cys680Arg mutation in the MLH1 mismatch repair protein. *Molecular Genetics & Genomic Medicine*, **2014**, 2, 352-5	2.3	1
48	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
47	Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study. *Blood*, **2014**, 124, 151-151	2.2	21
46	Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells. *Blood*, **2014**, 124, 812-812	2.2	9
45	Potential of Digital PCR in CML Calibration. *Blood*, **2014**, 124, 1817-1817	2.2	
44	Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. *Leukemia*, **2013**, 27, 1520-6	10.7	49
43	Whole-genome-amplified DNA as a source for mutational analysis underestimates the frequency of mutations in pediatric acute myeloid leukemia. *Leukemia*, **2013**, 27, 510-2	10.7	1
42	Analysis of mice lacking the heparin-binding splice isoform of platelet-derived growth factor A. *Molecular and Cellular Biology*, **2013**, 33, 4030-40	4.8	8
41	Dasatinib Treatment Induces Fast and Deep Responses In Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients In Chronic Phase: Clinical Results From a Randomized Phase 2 Study (NordCML006). *Blood*, **2013**, 122, 4032-4032	2.2	1
40	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
39	Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia. *American Journal of Hematology*, **2012**, 87, 361-7	7.1	11
38	Response: high ERG gene expression is an unfavorable prognostic marker in pediatric acute myeloid leukemia. *Blood*, **2012**, 119, 1087-1088	2.2	5
37	Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R63	8.3	15
36	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 136, 295-302	4.4	3
35	Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. *PLoS ONE*, **2012**, 7, e35706	3.7	10
34	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. *British Journal of Cancer*, **2012**, 106, 2016-24	8.7	25

33	Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. *Epigenetics*, **2012**, 7, 1435-42	5.7	29
32	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
31	Exploring the link between MORF4L1 and risk of breast cancer. *Breast Cancer Research*, **2011**, 13, R40	8.3	16
30	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110	8.3	62
29	Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey. *Annals of Surgery*, **2011**, 253, 1147-54	7.8	44
28	Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. *Blood*, **2011**, 118, 3228-35	2.2	145
27	The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trial. *Leukemia*, **2011**, 25, 622-8	10.7	21
26	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. *British Journal of Cancer*, **2011**, 104, 1356-61	8.7	6
25	Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. *Blood*, **2011**, 118, 5905-13	2.2	68
24	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. *Human Genetics*, **2011**, 130, 685-99	6.3	15
23	High-resolution genomic screening in mantle cell lymphoma--specific changes correlate with genomic complexity, the proliferation signature and survival. *Genes Chromosomes and Cancer*, **2011**, 50, 113-21	5	24
22	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 3304-21	5.6	62
21	Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1032-8	4	13
20	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 4732-47	5.6	21
19	Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. *Leukemia*, **2011**, 25, 1904-8	10.7	65
18	Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. *PLoS Biology*, **2011**, 9, e1001199	9.7	73
17	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
16	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54	10.1	147

15	How to handle genetic information: a comparison of attitudes among patients and the general population. *Public Health Genomics*, **2010**, 13, 396-405	1.9	6
14	Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2859-68	4	32
13	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. *Blood*, **2010**, 116, e111-7	2.2	120
12	Stability of Conversion Factors for BCR-ABL Monitoring - Implications for the Frequency of Validation Rounds. *Blood*, **2010**, 116, 893-893	2.2	3
11	Genome-Wide Array-Based Methylation Profiling Reveals Preferential Methylation of Homeobox Transcription Factor Genes In Mantle Cell Lymphoma and Pro-Apoptotic Genes In Chronic Lymphocytic Leukemia. *Blood*, **2010**, 116, 536-536	2.2	
10	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56	5.6	91
9	Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome. *Genes Chromosomes and Cancer*, **2009**, 48, 795-805	5	31
8	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). *British Journal of Cancer*, **2009**, 101, 2048-54	8.7	13
7	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. *Blood*, **2009**, 113, 4497-504	2.2	158
6	A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.. *Blood*, **2009**, 114, 3280-3280	2.2	1
5	U-2973, a novel B-cell line established from a patient with a mature B-cell leukemia displaying concurrent t(14;18) and MYC translocation to a non-IG gene partner. *European Journal of Haematology*, **2008**, 81, 218-25	3.8	4
4	A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling. *Nature Genetics*, **2004**, 36, 1111-6	36.3	174
3	PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. *Nature Cell Biology*, **2000**, 2, 302-9	23.4	493
2	PDGFB regulates the development of the labyrinthine layer of the mouse fetal placenta. *Developmental Biology*, **1999**, 212, 124-36	3.1	99
1	PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. *Cell*, **1996**, 85, 863-73	56.2	704